12.98
price up icon1.01%   0.13
after-market 시간 외 거래: 12.98
loading
전일 마감가:
$12.85
열려 있는:
$12.97
하루 거래량:
579.26K
Relative Volume:
1.45
시가총액:
$789.88M
수익:
$5.03M
순이익/손실:
$-185.41M
주가수익비율:
-4.7372
EPS:
-2.74
순현금흐름:
$-139.79M
1주 성능:
+4.42%
1개월 성능:
-11.28%
6개월 성능:
-8.46%
1년 성능:
-6.82%
1일 변동 폭
Value
$12.78
$13.32
1주일 범위
Value
$12.01
$13.32
52주 변동 폭
Value
$10.22
$19.62

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name
명칭
Pliant Therapeutics Inc
Name
전화
650-481-6770
Name
주소
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
직원
166
Name
트위터
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
PLRX's Discussions on Twitter

PLRX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
PLRX 12.98 789.88M 5.03M -185.41M -139.79M -2.74
VRTX 450.97 116.14B 10.63B -479.80M -1.35B 13.33
REGN 738.00 81.10B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.23B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.12B 3.30B -501.07M 1.03B 11.54

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-05-18 개시 Canaccord Genuity Buy
2023-04-13 개시 Robert W. Baird Outperform
2022-12-14 개시 Stifel Buy
2022-12-07 개시 JP Morgan Overweight
2022-09-01 개시 Citigroup Buy
2022-07-20 개시 SVB Leerink Outperform
2022-05-25 개시 Cantor Fitzgerald Overweight
2021-12-10 개시 Oppenheimer Outperform
2021-11-24 개시 RBC Capital Mkts Outperform
2021-11-03 개시 H.C. Wainwright Buy
2021-04-20 개시 BTIG Research Buy
2021-04-05 개시 Citigroup Buy
2020-06-29 개시 Citigroup Buy
2020-06-29 개시 Cowen Outperform
2020-06-29 개시 Needham Buy
2020-06-29 개시 Piper Sandler Overweight
모두보기

Pliant Therapeutics Inc 주식(PLRX)의 최신 뉴스

pulisher
Nov 21, 2024

Pliant Therapeutics to Participate in Upcoming Investor Events - The Manila Times

Nov 21, 2024
pulisher
Nov 21, 2024

Pliant Therapeutics to Present at 4 Major Healthcare Conferences in December | PLRX Stock News - StockTitan

Nov 21, 2024
pulisher
Nov 18, 2024

Pliant Therapeutics Reports Increased Losses and Strategic Focus - TipRanks

Nov 18, 2024
pulisher
Nov 18, 2024

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024 - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Pliant's Bexotegrast Shows Strong Phase 2 Results in Liver Disease Treatment Trial | PLRX Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 15, 2024

Redmile Group, LLC Adjusts Stake in Pliant Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

First Light Asset Management's Strategic Reduction in Pliant The - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Objective long/short (PLRX) Report - Stock Traders Daily

Nov 14, 2024
pulisher
Nov 11, 2024

Pliant Therapeutics maintains stock target with Buy rating on clinical trial - Investing.com UK

Nov 11, 2024
pulisher
Nov 08, 2024

Stifel maintains Buy on Pliant Therapeutics, target at $32 By Investing.com - Investing.com UK

Nov 08, 2024
pulisher
Nov 08, 2024

HC Wainwright Reiterates "Buy" Rating for Pliant Therapeutics (NASDAQ:PLRX) - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Pliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

Possible Bearish Signals With Pliant Therapeutics Insiders Disposing Stock - Simply Wall St

Nov 07, 2024
pulisher
Nov 07, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Harbor Capital Advisors Inc. - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Pliant Therapeutics to Participate in the Stifel Healthcare Conference - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Pliant Therapeutics to Present at Stifel 2024 Healthcare Conference | Key Leadership Insights | PLRX Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 03, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Nov 03, 2024
pulisher
Nov 03, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Nov 03, 2024
pulisher
Oct 21, 2024

Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 5.4%Time to Sell? - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

SG Americas Securities LLC Decreases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Oct 21, 2024
pulisher
Oct 17, 2024

Pliant reports positive Phase 2a trial results for liver disease drug - Investing.com Australia

Oct 17, 2024
pulisher
Oct 17, 2024

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating - GlobeNewswire

Oct 17, 2024
pulisher
Oct 17, 2024

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024 - Yahoo Finance

Oct 17, 2024
pulisher
Oct 15, 2024

Pliant Therapeutics Inc (PLRX)’s stock price in review: A technical analysis - US Post News

Oct 15, 2024
pulisher
Oct 14, 2024

Pliant Therapeutics Inc’s Mixed Bag: Down -3.53% in 6 Months, Down 15.29% in 30 Days - The InvestChronicle

Oct 14, 2024
pulisher
Oct 14, 2024

An Analysis of Pliant Therapeutics Inc (PLRX)’s Potential Price Growth - Knox Daily

Oct 14, 2024
pulisher
Oct 14, 2024

The Manufacturers Life Insurance Company Purchases 1,191 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Oct 14, 2024
pulisher
Oct 13, 2024

How To Trade (PLRX) - Stock Traders Daily

Oct 13, 2024
pulisher
Oct 09, 2024

Pliant Therapeutics (NASDAQ:PLRX) Trading 4.5% HigherStill a Buy? - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

Pliant Therapeutics Inc [PLRX] Stock sold by Insider Lefebvre Eric for $0.14 million - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Oct 09, 2024
pulisher
Oct 07, 2024

Squarepoint Ops LLC Takes $865,000 Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat

Oct 07, 2024
pulisher
Oct 06, 2024

Algert Global LLC Increases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat

Oct 06, 2024
pulisher
Oct 04, 2024

Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc - Yahoo Finance

Oct 04, 2024
pulisher
Oct 02, 2024

Pliant Therapeutics stock hits 52-week low at $10.24 - Investing.com

Oct 02, 2024
pulisher
Oct 02, 2024

Pliant Therapeutics appoints new SVP of Medical Affairs - Investing.com India

Oct 02, 2024
pulisher
Oct 02, 2024

Pliant Therapeutics stock hits 52-week low at $10.24 By Investing.com - Investing.com Australia

Oct 02, 2024
pulisher
Oct 02, 2024

Pliant Therapeutics (NASDAQ:PLRX) Sets New 12-Month Low at $10.24 - MarketBeat

Oct 02, 2024
pulisher
Oct 02, 2024

Pliant Therapeutics (NASDAQ:PLRX) Hits New 1-Year Low at $10.24 - Defense World

Oct 02, 2024
pulisher
Oct 02, 2024

Investor’s Toolkit: Key Ratios for Assessing Pliant Therapeutics Inc (PLRX)’s Performance - The Dwinnex

Oct 02, 2024
pulisher
Oct 02, 2024

American Century Companies Inc. Has $797,000 Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Oct 02, 2024
pulisher
Oct 01, 2024

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs - GlobeNewswire

Oct 01, 2024
pulisher
Oct 01, 2024

Lululemon Athletica (LULU-Q) QuotePress Release - The Globe and Mail

Oct 01, 2024
pulisher
Oct 01, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Renaissance Technologies LLC - Defense World

Oct 01, 2024
pulisher
Sep 30, 2024

Ensign Peak Advisors Inc Grows Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Sep 30, 2024
pulisher
Sep 30, 2024

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Bakersfield Californian

Sep 30, 2024
pulisher
Sep 30, 2024

11,678 Shares in Pliant Therapeutics, Inc. (NASDAQ:PLRX) Acquired by Deerfield Management Company L.P. Series C - Defense World

Sep 30, 2024

Pliant Therapeutics Inc (PLRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Pliant Therapeutics Inc 주식 (PLRX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Hull Hans
Chief Business Officer
Jul 10 '24
Sale
11.56
9,900
114,444
227,494
Cummings Keith Lamont
Chief Financial Officer
Jul 10 '24
Sale
11.56
10,911
126,131
282,115
Coulie Bernard
President and CEO
Jul 10 '24
Sale
11.56
38,710
447,488
482,936
Ouimette Mike
General Counsel & Corp. Sec'y
Jul 10 '24
Sale
11.56
7,656
88,503
94,044
Cummings Keith Lamont
Chief Financial Officer
May 02 '24
Option Exercise
2.08
21,000
43,680
271,713
Cummings Keith Lamont
Chief Financial Officer
Jan 17 '24
Sale
17.23
9,781
168,527
194,605
Hull Hans
Chief Business Officer
Jan 17 '24
Sale
17.23
9,786
168,613
185,069
Coulie Bernard
President and CEO
Jan 17 '24
Sale
17.23
25,721
443,173
316,382
Lefebvre Eric
Chief Medical Officer
Jan 17 '24
Sale
17.23
10,295
177,383
156,920
Ouimette Mike
General Counsel & Corp. Sec'y
Jan 17 '24
Sale
17.23
5,197
89,544
55,246
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
자본화:     |  볼륨(24시간):